- Home
- FONR vs ATOS Comparison
FONR vs ATOS Comparison
Compare FONR & ATOS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FONR | ATOS |
|---|---|---|
| Founded | 1978 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.9M | 100.8M |
| IPO Year | 1987 | 2012 |
Fundamental Metrics
Financial Performance| Metric | FONR | ATOS |
|---|---|---|
| Price | $18.56 | $0.66 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.33 |
| AVG Volume (30 Days) | 125.5K | ★ 1.5M |
| Earning Date | 02-17-2026 | 11-12-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.08 | N/A |
| Revenue | ★ $105,434,318.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $17.10 | ★ N/A |
| Revenue Growth | ★ 3.36 | N/A |
| 52 Week Low | $12.00 | $0.55 |
| 52 Week High | $18.86 | $1.29 |
Technical Indicators
Market Signals| Indicator | FONR | ATOS |
|---|---|---|
| Relative Strength Index (RSI) | 80.82 | 43.02 |
| Support Level | $18.50 | $0.55 |
| Resistance Level | $18.86 | $0.70 |
| Average True Range (ATR) | 0.17 | 0.04 |
| MACD | 0.36 | 0.00 |
| Stochastic Oscillator | 93.16 | 56.67 |
Price Performance
Historical ComparisonAbout FONR Fonar Corporation
Fonar Corp is a United States-based company which is engaged in the business of designing, manufacturing, selling and servicing magnetic resonance imaging (MRI) scanners, which utilize MRI technology for the detection and diagnosis of human disease, abnormalities, other medical conditions, and injuries. The company operates through two segments namely Manufacturing and servicing of medical equipment; and the Management of diagnostic imaging centers, which generates a vast majority of the revenue.
About ATOS Atossa Therapeutics Inc.
Atossa Therapeutics Inc is a clinical stage biopharmaceutical company developing proprietary medicines in areas of unmet medical need in oncology. It focuses on the development of novel therapeutics and delivery methods for the treatment of breast cancer, other breast conditions and COVID-19. The company's drug under development for breast cancer and other breast conditions is Endoxifen. Its two COVID-19 drugs under development are AT-H201, to improve lung function of moderate to severely ill, hospitalized COVID-19 patients by inhalation; and AT-301, a nasal spray for COVID-19 patients for at-home use.